knowledge -WSS

knowledge

author：entertainment 2025-09-10 04:17:12 - browse：3

U.S. President Joe Biden stands with his fingers locked next to an US flag — politics coverage from STAT — President Biden's White House on Monday ballyhooed a routine step in Medicare’s new program to negotiate the prices of prescription drugs.

WASHINGTON — The White House on Monday ballyhooed a routine step in Medicare’s new program to negotiate the prices of prescription drugs, its latest effort to draw attention to the program in an election year.

The news is not controversial: The pharmaceutical companies that make the first ten drugs up for negotiation all submitted counteroffers. It’s an incremental step in the new program, which was created in 2022.

Earlier this year, Medicare sent its initial price offers to the companies. Neither the Biden administration nor the drug manufacturers have volunteered any information about the White House’s initial price offers or the counteroffers. The process is scheduled to end by Aug. 1.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Data don't support strong claims for Covid

hotspot

WSS

Videos point to link between seizures and unexplained toddler deaths

Structure Therapeutics oral GLP

BD to buy Edwards patient monitoring unit for $4.2 billion

The biotech scorecard for Q1: 17 stock

JPM 2024 Day 3: Biotech Updates from Verve, Roivant, etc

UCB departs biotech trade group BIO

knowledge

knowledge

knowledge

George Santos makes 1st court appearance after pleading not guilty to 13 counts

JPM 2024 Day 3: Biotech Updates from Verve, Roivant, etc

BioMarin wins approval for gene therapy to treat hemophilia A

Sutter Health’s antitrust win overturned by appeals court

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Morgan Health, with ambitious aims, wants you to know it’s still here

Moonlake's readout produced a cash windfall. Risks remain

The most pressing bird flu mysteries scientists want answered

Trump demands the U.S. pay no more for drugs than other countries … again

Data don't support strong claims for Covid

entertainment

Ahead of JPM, here's who's profiting most in health care

JPM: CVS says Medicare Advantage patients are impacting profits

Goldman Sachs launches $650M fund for life science investments

ASCO Takeaways: Winners, snoozers, and the art of cancer care

UCB departs biotech trade group BIO

UnitedHealth CEO's Medicaid comments send insurer stocks diving

focus

hotspot

leisure time

knowledge